Table 1.
pSS with Fanconi syndrome | pSS with TIN | P value* | |
---|---|---|---|
(N = 12) | (N = 20) | ||
Age (years) | 39.3 ± 8.6 | 37.6 ± 12.2 | 0.366 |
Gender (female %) | 10 (83.3) | 18 (90.0) | 0.620 |
Presenting symptoms | |||
Polyuria | 8 (66.7) | 10 (50.0) | 0.471 |
Muscle weakness | 9 (75.0) | 14 (70.0) | 1.000 |
Nocturia | 7 (58.3) | 5 (25.0) | 0.130 |
dRTA | 9 (75.0) | 11 (55.0) | 0.452 |
Paralysis | 3 (25.0) | 6 (30.0) | 1.000 |
SCr elevation | 9 (75.0) | 12 (60.0) | 0.465 |
eGFR (ml/min/1.73 m2) | 66.08 ± 38.20 | 76.14 ± 39.57 | 0.716 |
Serum potassium (mmol/L) | 2.79 ± 0.14 | 2.76 ± 0.24 | 0.120 |
Serum calcium (mmol/L) | 2.23 ± 0.14 | 2.13 ± 0.09 | 0.104 |
Serum phosphorus (mmol/L) | 0.69 ± 0.33 | 1.02 ± 0.29 | 0.001 |
24-h urine protein (g/24 h) | 1.51 ± 0.84 | 1.00 ± 0.61 | 0.019 |
Systemic manifestations | |||
ESSDAI | 18.83 ± 7.83 | 15.50 ± 6.53 | 0.289 |
Weight loss (>5%) | 7 (58.3) | 6 (30.0) | 0.150 |
Glandular | 2 (16.7) | 3 (15.0) | 1.000 |
Cutaneous | 1 (8.3) | 1 (5.0) | 1.000 |
Pulmonary | 1 (8.3) | 3 (15.0) | 1.000 |
Lymphadenopathy | 0 (0.0) | 2 (10.0) | 0.516 |
HGB (g/L) | 105.3 ± 25.2 | 113.4 ± 13.6 | 0.408 |
Immune profile | |||
ESR (mm/h) | 58.8 ± 30.9 | 42.7 ± 30.9 | 0.141 |
ANA positive | 9 (75.0) | 18 (90.0) | 0.338 |
SSA positive | 5 (41.7) | 14 (73.7) | 0.130 |
SSB positive | 3 (25.0) | 19 (47.1) | 0.273 |
IgG (g/L) | 18.3 ± 8.2 | 19.7 ± 6.3 | 0.588 |
Data presented as number (%) or mean ± SD unless otherwise noted
ANA antinuclear antibody, dRTA distal renal tubule acidosis, eGFR estimated glomerular filtration rate, ESR erythrocyte sedimentation rate, ESSDAI Eular Sjogren’s Syndrome Disease Activity Index, HGB hemoglobin, IgG immunoglobulin G, pSS primary Sjogren syndrome, SCr serum creatinine, SSA Sjogren-syndrome-related antigen A, SSB Sjogren-syndrome-related antigen B, TIN tubulointerstitial nephritis
*Mann–Whitney (two-tailed) test for continuous variables and Fisher’s exact (two-tailed) test for categorical variables